Intracellular organelles, including secretory vesicles, emerged when eukaryotic cells evolved some 3 billion years ago. The primordial organelles that evolved in Archaea were similar to endolysosomes, which developed, arguably, for specific metabolic tasks, including uptake, metabolic processing, storage and disposal of molecules. In comparison with prokaryotes, cell volume of eukaryotes increased by several orders of magnitude and vesicle traffic emerged to allow for communication between distant intracellular locations. Lysosomes, first described in 1955, a prominent intermediate of endo-and exocytotic pathways, operate virtually in all eukaryotic cells including astroglia, the most heterogeneous type of homeostatic glia in the central nervous system. Astrocytes support neuronal network activity in particular through elaborated secretion, based on a complex intracellular vesicle network dynamics. Deranged homeostasis underlies disease and astroglial vesicle traffic contributes to the pathophysiology of neurodegenerative (Alzheimer's disease, Huntington's disease), neurodevelopmental diseases (intellectual deficiency, Rett's disease) and neuroinfectious (Zika virus) disorders. This review addresses astroglial cell-autonomous vesicular traffic network, as well as its into primary and secondary vesicular network defects in diseases, and considers this network as a target for developing new therapies for neurological conditions.
post-lesion regeneration of neural networks 3, 11, 13 although it may be also neurotoxic in some circumstances. 19 Moreover, astrocytes are a part of the glymphatic system, regulating the convective removal of waste accumulated in the extracellular space.
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Signalling between astrocytes and other cellular elements of the CNS is mainly mediated through the release of chemical messengers. Astroglial cells secrete a surprisingly large number of molecules, including neurotransmitters and their precursors, neurohormones, trophic, plastic and growth factors, scavengers of reactive oxygen species, immunoactive molecules and pro-inflammatory factors and many more. 16, 21, 22 Mechanisms of astroglial secretion are complex and include vesicular exocytosis, diffusion through plasmalemmal channels and plasmalemmal transporters. 12, 16 Thus, astrocytes represent a gliocrine system, 22 responsible for regulation of the CNS microenvironment through the secretion of neuroactive compounds. The role for secretory organelles is, however, substantially wider than a simple export of various cargos; different types of cytosolic vesicles contribute to endocytosis and delivery of proteins to plasmalemma, whereas an impairment of vesicular traffic results in multiple neuropathologies.
Evolution of secretory organelles
Life forms belong to the Domains (also known as Superkingdoms) of Bacteria, Archaea and Eukarya. 23, 24 It is almost universally accepted that secretory organelles exist solely in eukaryotic cells, the notion which requires critical assessment. The origin and appearance of eukaryotes remains debatable 25, 26 and their immediate predecessors (e.g. archaebacteria or eubacteria 27 ) are not yet unequivocally identified.
Similarly disputed is the geological age of eukaryote emergence; eukaryotic signatures have been recovered in fossils of 3-3.5 billion years of age, 28 this being substantially older than generally accepted time of eukaryote emergence~2 billion years ago. This may indicate a very early divergence of the Domains of Life. Incidentally, the intermediate form lying in between Archaea and Eukarya, the 'chronocyte', has also been suggested. 29 Cytological structure of Bacteria and Archaea is relatively uncomplicated. How Eukarya, characterized by a significant degree of cellular structural complexity developed from Archaea, 30 is unclear, although most hypotheses assume a prokaryote-to-eukaryote transition or else an integration of an archaebacterium into a eubacterium. Conceptually, the eukaryote evolution is linked to the presence of mitochondrionlike structures and/or mitochondrial proteins. It seems, however, possible that aerobic and anaerobic eukaryotes, harbouring mitochondrial homologues of various sorts, have co-existed throughout eukaryote history. 31 The hypothesis that Eukarya emerged from an ancestral Archaea has recently gained interest, in particular after subcellular organelles other than mitochondria were recognized in the early life forms. Indeed, the discovery of 'Lokiarchaeota', a novel phylum, with genes encoding an array of eukaryotic signature proteins that are required for membrane plasticity supports this view. 30 Specifically, this ancestral Archaea expressed genes encoding particular proteins, which in Eukarya contribute to remodelling of cell shape and membrane deformation including phagocytosis, a form of endocytosis, where molecules or particles are transported into the cell involving vesicles pinching off the plasma membrane. 32 This process requires cytoskeletal elements such as actin; the Lokiarchaeum genome encodes five actin homologues with high similarity to eukaryotic actin and actinrelated proteins. 30 Key regulators of actin cytoskeleton dynamics are small GTPases, which are essential for vesicle traffic. 33 A substantial presence of Ras-superfamily GTPases, which account for nearly 2% of the proteome, has been identified in Lokiarchaeota. 30 This
Archaean phylum also contains genes for endosomal sorting complexes required for transport proteins, as well as components of the eukaryotic multivesicular body belonging to the endosome pathway required for the biogenesis of lysosomes, directing plasma membrane proteins for lysosomal degradation, acting in viral budding, in cytokinesis, autophagy and other pathways. 34 Identification of archaeal genes involved in membrane remodelling and vesicular trafficking indicates that the emergence of subcellular organelles, resembling endolysosomal structures, was already under way before the acquisition of the mitochondrial endosymbiont.
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The lysosomal network
Lysosomes are dedicated organelles of endo-and exocytotic pathways, which operate in nearly all animal and plant cells. The term 'lysosome' was introduced in 1955 35 from Ancient Greek 'kύrις' -'to loosen', and 'rῶlά' -body, that is a 'lytic or digestive body', as several degrading enzymes have been found in this structure. 36, 37 To visualize this new organelle, a staining method for acid phosphatase was used, and the location of these enzymes in the lysosome was confirmed by electron microscopy. 38 An important insight about the degrading function of lysosomes, which contains many hydrolytic enzymes, came from the discoveries that molecules present in the extracellular space can enter the cell via endocytosis. Fragments of the labelled extracellular proteins were found localized in lysosomes.
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Until recently, it was thought that lysosomes are merely responsible for catabolism, as they contain hydrolytic enzymes. Besides degradation of biomolecules, however, the lysosome is involved in energy metabolism, in secretion, in delivery of membrane receptors to the plasma membrane, in plasma membrane repair and in cell signalling. All this is possible as lysosomes actively fuse ( Fig. 1 ) with other cellular structures including the plasmalemma, late endocytotic vesicles, and autophagosomes; the latter haul intracellular material for degradation. Membrane transporters translocate metabolites, ions and soluble substrates into and out of lysosomes. 37 The central position of lysosome is not only linked to the endocytotic entry of molecules into the cell but also to teh exocytotic exit of molecules (Fig. 1) . Incidentally, the terms 'autophagy' (for lysosomal degradation of materials of the intracellular origin), 'endocytosis' (for lysosomal digestion of materials of the extracellular origin) and 'exocytosis' were all introduced at a meeting in London in 1963, 36 which followed lysosomes discovery. The complex lysosomal vesicular network is also present in astrocytes. The integrating role of glial communication in the CNS resembles, to some extent, the function of the endocrine system, a master regulator of bodily functions, which operates substantially slower than rapid, often sub-millisecond, synaptic neuronal signalling. Therefore, astroglia were proposed to constitute the gliocrine system within the CNS. 16, 22 Another similarity between the endocrine and the gliocrine systems lies in the manner of signalling molecules delivery to the appropriate targets. Hormones are transported by blood circulation, while gliosignalling molecules, secreted by astroglia into the interstitium, can be convectively transferred by the recently described glymphatic apparatus. 20 Thus, astroglial vesicular networks contribute to the tissue-wide array of processes, all fundamental to normal and pathological CNS conditions.
Astrocytes and vesicle traffic

Astroglial endocytosis
Endocytosis consists of many processes and contributes to a multitude of cellular functions including uptake of extracellular nutrients, regulation of cell surface receptor presence, which shapes the plasmalemmal signalling landscape, and antigen presentation. 
Extracellular debris removal by astroglial endocytosis
The removal of waste materials and debris from the extracellular space is in part the function of endocytosis coupled with the convective flow of the glymphatic system, an important clearance mechanism, depending on aquaporin 4 (AQP4) water channel. [56] [57] [58] Although the position of AQP4 in the brain appears to be important in determining water transport in the brain, 59 it is still unclear how AQP4 participates in the convective flow of extracellular solution through the brain and spinal cord parenchyma, which appears key in ensuring CNS homeostasis and contributes to pathological conditions as occurring in cerebral ischaemia, neurotrauma, cytotoxic oedema, epilepsy, Parkinson's and Alzheimer's diseases, in which the BBB is compromised. [60] [61] [62] Debris that accumulates in the CNS due to transfer from the systemic circulation through the BBB or due to pathological events within the CNS itself, coupled to diffusion, fluxes along the relatively long tortuous extracellular space of the brain interstitium and may be taken into astroglial vesicle network by endocytosis. Astroglial endocytic and lysosomal network can be fundamental for the removal of cellular detritus and toxic macromolecules both in physiological and in pathological context. In a multitude of diseases/conditions associated with myelin destruction, which include multiple sclerosis, progressive multifocal leukoencephalopathy, metachromatic leukodystrophy and subacute infarct, astrocytes accumulate myelin debris by means of cell surface scavenger receptor low-density lipoprotein receptor-related protein 1 receptor-mediated endocytosis. 63 In neurotrauma, for example, cytoplasmic proteins exit into the extracellular space. This may result in additional toxicity, with these proteins exerting further damaging effects on neighbouring cells. The capacity of astrocytes to internalize S100B, a protein secreted by astrocytes, 69 was studied recently. 70 Fluorescently labelled S100B (S100B-Alexa Fluor â 488, Thermo Fisher Scientific, Waltham, MA, USA) was added to the cultured astrocytes, and cells were monitored by time-lapse confocal microscopy. The S100B was found to enter cells, with subsequent trafficking via endocytotic vesicles. The entry of S100B-Alexa 488 involved, at least in part, the 'scavenger receptor' RAGE, as pre-treatment with anti-RAGE antibody partially prevented the uptake of S100B-Alexa Fluor â 488. Endocytotic uptake of S100B-Alexa Fluor â 488 was also suppressed by a dynamin inhibitor Dynole 34-2. As described previously, 71 endolysosomal traffic exhibits directional and non-directional vesicle mobility, and this was also observed for endocytotic vesicles taking up S100B-Alexa Fluor â 488. 70 Directional mobility of S100B-Alexa Fluor â 488-positive vesicles increased over time as did the colocalization of this protein with a lysosomal marker, indicating the transport of the internalized protein into this compartment. 70 
Exocytotic vesicles in astroglia
Although astroglial vesicle-mediated release of chemical messengers is well documented, this mechanism, however, is distinct from that operational in neurones, especially when the kinetics is considered. 12, 16, 49, 72 Following the pioneering studies that revealed astroglial release of glutamate in a Ca 2+ -dependent manner, 73 the role of vesicular secretion of gliosignalling molecules was analysed in vesicles containing fluorescently labelled atrial natriuretic peptide (ANP) 50 and by monitoring membrane capacitance, a parameter linearly related to membrane area 74 and sufficiently sensitive to detect unitary vesicle fusion/fission events in real time in isolated 75, 76 and also in astrocytes in tissue slices. 77 However, there has been comprehensive coverage on the size and nature of vesicles in astrocytes elsewhere, 10, 16, 18 using electron microscopy and fluorescence markers. 68, [78] [79] [80] [81] Here, we focus on a recent study, where the super-resolution fluorescence microscopy was combined with the high-resolution membrane capacitance monitoring, 82 compellingly demonstrating the existence of two populations of secretory vesicles (distinct in their size) in cultured and freshly isolated rat astrocytes ( Figure 2 ). Small vesicles (~70 nm in diameter) mainly contain amino acids glutamate (based on labelling of the vesicular glutamate transporter 1; V-GLUT1) and/or peptides (brain-derived neurotrophic factor -BDNF and ANP), whereas ATP and some peptides are present mainly in larger (~200 nm in diameter) lysosome-associated compartments (marked by antibody against the lysosomal-associated membrane protein LAMP-1 and by quinacrine (which binds to adenine nucleotides), as was already reported previously. 83 This separation of vesicular populations was not dependent on animal age, because similar results were obtained in astrocytes deriving from post-natal as well as from adult animals. The larger vesicles that contain peptides and ATP may well be generated by the fusion of peptidergic vesicles that arise from the Golgi cisternae with some endosomes and/or lysosomes. Vesicles of all sizes in astrocytes interact with the plasma membrane, as was monitored by discrete increases in membrane capacitance. As was already noted for endocrine cells, 84 transient exocytotic fusions were more abundant than the full-fusion exocytotic events, especially after stimulation of cells, which facilitates conversion of transient fusion events to full-fusion events predominantly in larger vesicles. 82 This vesicle size-dependent mechanism of unitary exocytotic events is not due to a different density of SNARE molecules in larger and smaller vesicles, 85 but it more likely reflects vesicle size-dependent stability of fusion pores, which appear more stable in smaller vesicles. 86 
Regulation of vesicle network dynamics in astrocytes
Vesicular dysfunction in neurological diseases
Vesicle traffic associates with numerous functions of astrocytes including regulation of the plasma membrane density of receptors, pumps, transporters, is involved in changes in morphological plasticity and in cell degradation pathways. Impairment of the vesicle network dynamics hence may contribute to astrogliopathies. 91 Primary and secondary vesicle network defects Alterations in vesicle dynamics may develop as side effects of medication, for example, in multiple sclerosis treated with FTY 720 121 or when using ketamine, an anaesthetic and antidepressant, 105 which also affects vesicle merger with the plasma membrane.
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The secondary vesicle network defects are associated with abnormalities of carried cargo. Enzymatic deficits result in impaired processing of metabolic intermediates, which are transported in vesicles leading to the accumulation of the non-degraded cargo in the vesicular compartment that may disrupt (jam) the vesicle network as a whole (Fig. 1) . In support that the vesicle network defects are of two kinds, primary and secondary, experiments, where a combination of cytoskeleton alteration and an enzymatic deficit was introduced to study infantile neuronal ceroid lipofuscinosis (INCL), an inherited neurodegenerative disorder, caused by mutations in the lysosomal hydrolase, palmitoyl protein thioesterase 1 (PPT1), revealed that if both the intermediate filament cytoskeleton (with deleted glial acidic fibrillary protein (GFAP) and vimentin) and PPT1 were impaired, the INCL progressed more rapidly. 123 Malfunction of hydrolytic enzymes, such as PPT1, impairs lysosomal degrading pathway; this impairment lies at the core of extended (more than 60 members) family of lysosomal storage diseases. 124, 125 Roughly two-thirds to three-quarters of lysosomal storage diseases are neuropathic. 126 Neurological disorders resulting from lysosomal pathology include neuronal ceroid lipofuscinoses (or Batten disease), Krabbe disease, Gaucher disease, Sandhoff disease, NiemannPick (NP) type C, Tay-Sachs disease. 127 In Tay-Sachs disease, there is a deficiency of hexosaminidase A, a vital lysosomal hydrolytic enzyme, degrading glycolipids. 128 As a result, these lipids accumulate, and this intracellular accumulation affects normal cell function 131 whereas Krabbe disease is associated with the deficiency of b-galactocerebrosidase. 126 In the context of lysosomal storage diseases, astrocytes demonstrate either reactive phenotypes or apoptotic death, both of which possibly associate with abnormalities of the lysosomal network. 126 Astroglial reactive remodelling sometimes occurs at the early pathological stages preceding (and possibly precipitating) neuronal death; such an early activation is observed, for example, in juvenile Batten disease. 132 Considerable lysosomal pathology was observed in astrocytes in the context of multiple sulfatase deficiency that causes severe neurodegeneration. Deficient astroglial lysosomal network affects autophagy and is linked to decreased neuronal survival. 133 In contrast to secondary vesicle network impairments, vesicle dynamics in primary network defects may be directly affected by changes in cytoskeleton along which vesicles are transported. As mentioned previously, vesicles exhibit directional and non-directional mobility. The former depends on intact cytoskeleton 107 and impairments in the linking of vesicles to cytoskeleton as well as changes in cytoskeleton may lead to pathology. This means that vesicle network dynamics may be a target for treatments.
Neurotropic viruses use endocytosis to enter astrocytes
The rise of Zika virus (ZIKV) epidemic in the Central and South Americas enticed refreshed interest into how the virus, linked with microcephaly (severe underdevelopment of the cerebral cortex in newborn babies from infected mothers 134 ), instigates this neurodevelopmental disorder. As shown previously, the TBEV, a human pathogen that causes neuroinfections in Europe and Asia, [135] [136] [137] infects astroglia, after entering astrocytes by endocytosis. 116 The TBEV and ZIKV are members of the Flaviviridae family. 134, 138 A similar mechanism of entry into astrocytes (although it is yet to be fully characterized) underlies ZIKV neurotropism. Again, similar mechanism underlies astroglial infection with human immunodeficiency virus 1 (HIV-1), which enters astroglia by endocytosis; however, the HIV-1 virus seems to be effectively destroyed in the astroglial lysosomal pathway. 139 Mechanisms of TBEV entry into rodent astrocytes are complex. 116 First, to invade the CNS, a neurotropic virus must negotiate the BBB, which protects the CNS tissue from the direct ingress of viruses circulating in the blood. 137, 140 Astrocytes are a key component of the BBB, with astroglial endfeet providing almost complete coverage of the intracranial vasculature. Astrocytes are positioned between synapses and blood vessels, contributing to neurovascular coupling. 141, 142 Infection with TBEV does not affect astroglial viability; to the contrary, astrocytes likely serve as a reservoir for TBEV supporting re-infection. 116 Second, preferential viral infection of astroglia likely reflects the fact that astrocytes provide a favourable environment for virus replication, possibly because they are a site with a special adaptation of glycolysis. Aerobic glycolysis, characteristic of astroglia, also exists in rapidly dividing cells and in cells undergoing plastic morphological changes, despite the presence of adequate levels of oxygen, a phenomenon known as 'the Warburg effect'. 143 This form of metabolism is far from being efficient for ATP production; however, it provides biosynthetic intermediates, thus being advantageous for developing and growing tissues. 144 Aerobic glycolysis, primarily taking place in astrocytes in the CNS, is operative during neurodevelopment and even in adulthood in some areas of the CNS. 145 Therefore, this property of astrocytes may be associated with the preferential infection of astrocytes by neurotropic viruses, such as ZIKV. Intra-astrocytic traffic of TBEV within the endosomal system was monitored in real time. 116 As depicted in Figure 3 , TBEV particles associate with early endosomes and later, during the post-infection time, also with lysosomes as revealed by colocalization of TBEV particles with endosomal (early endosome antigen 1) and lysosomal LAMP1 markers. Similar to secretory vesicles, 87 endocytosed TBEVcontaining vesicles exhibit two forms of mobility in living astrocytes, directional and non-directional. The former likely reflects vesicular transport with protein motors along the cytoskeletal elements, such as microtubules, actin and intermediate filaments, including astroglia-specific GFAP. 107 In contrast, the mobility of non-directional vesicles is determined by free diffusion. 87 Prolongation of the post-infection time not only increased the number of TBEV particles within an astrocyte, but also resulted in increased TBEV particle mobility. 116 Endocytosis was recently confirmed to be the mechanism of ZIKV infection of astrocytes and microglia. 146 The membrane protein Axl, a member of the Tyro3 Axl Mer family of proteins, exhibiting tyrosine kinase receptor activity, regulating innate immunity and the removal of apoptotic cells, 147 plays a role in targeting glia. 146 As Axl is abundantly expressed in glial but not in neural progenitor cells, this indicates a preferential cellular tropism for ZIKV infection. 146 Future experiments should aim to confirm that neurovirulence of ZIKV and other flaviviruses is associated mainly with astroglia, including radial glia, which are fundamental for the development of the human neocortex, which involves the activity of locus coeruleus (LC). 148 The release of noradrenaline/norepinephrine from LC neurones activates aerobic glycolysis in astrocytes, monitored as an increase in cytosolic glucose concentration, 149 leading to the production of L-lactate. 150 The increased levels of L-lactate feed back to the LC neurones, 151 an interesting glio-neuronal communication where L-lactate serves as a signal. familial AD-associated mutated PS1 M146V gene. Eventually, altered properties of vesicle mobility may result in reduced peptide secretion, contributing to the development of neurodegeneration. 110 Moreover, a recent study, where mutated huntingtin caused impaired peptidergic secretion in HD, 111 is supporting the view that vesicle traffic defects may lead to neurodegeneration. 91 In addition to a reduced capacity of vesicular release of peptidergic and various chemical messengers from astrocytes, other vesicle-based mechanisms might contribute to the evolution of neurodegeneration. A prominent histopathological sign of AD is the extracellular accumulation of b-amyloid, which may be associated with a reduced capacity for removal or degrading mechanisms. 153 An important factor that may decrease b-amyloid deposits is the release of proteolytic enzymes from exocytotic lysosomes, which degrade the b-amyloid peptide in the extracellular space. Insulin-degrading enzyme (IDE) is such an enzyme secreted from neurones in the healthy brain. 154 In astrocytes, the secretion of IDE can be increased by an autophagy-dependent way by statins, a process likely leading to statin-induced degradation of extracellular b-amyloid peptide Ab40, which depends on IDE secretion from primary astrocytes. 155 Therefore, it appears that in AD, the function of IDE secretion by astrocytes is reduced in comparison with astrocytes in healthy subjects, consequently leading to increased deposits of b-amyloid. The mechanism of reduced secretion of IDE in AD is possibly mediated by an impaired interaction between autophagosomes and lysosomes, 153 an interaction needed to facilitate lysosomes to become competent for exocytosis. 37 The reduced capacity for release of IDE by astrocytes may mirror a general vesicle traffic defect associated with a lysosomal involvement in injury repair in astrocytes. 156 In the vicinity of plaques and b-amyloid deposits, astrocytes attain a reactive phenotype with overexpressed intermediate filaments. 157 
Neurodegeneration and vesicle traffic deficits
Neurodevelopment-related diseases and vesicle traffic
Vesicle traffic is strongly involved in neurodevelopment, 163 for example, by regulating cell migration during the neocortex formation. 164 Thus, when a neurotoxic attack or a viral infection impairs vesicle dynamics, neurodevelopmental defects (such as the microcephaly associated with ZIKV infection) may follow. 134 In neurodevelopmental diseases, such as in ID, a form of mental retardation characterized with low (<85) IQ, vesicle traffic disturbances may be the key cellular defect. The only manifest sign in non-specific ID is a reduced cognitive potential, which when presented together with other clinical signs and symptoms may compose a syndrome (e.g. Down syndrome), or may be associated with mitochondrial, developmental or metabolic deficits. 165 Symptoms of X-linked forms of ID (XLID), which appear early in life, are affecting a fair number of subjects; XLID is present in around 2% of the population. 166 One of the first mutated genes discovered in patients with XLID is GDI1, 167 which encodes the aGDI, a regulatory protein of monomeric GTPases, such as the family of Rab proteins. The aGDI protein retrieves the inactive, GDPbound form of Rab proteins, from the membrane. Rab GTPases are important vesicle traffic regulators. 168 Therefore, when the causal role for GDI1-mutated gene in ID was identified, this suggested that vesicular traffic in neuronal synapses is affected. 169, 170 Astrocytes express aGDI, and vesicle traffic in astrocytes carrying a mutation in GDI1 revealed an impaired vesicle phenotype; vesicle directionality index was reduced, revealing a less efficient coupling of vesicles to the cytoskeleton. 115 These results are consistent with previously published data, where the role of mutated Rab 4 and Rab 5 monomeric GTPases, both regulated by aGDI protein, was studied by Potokar et al. 114 How the impaired endolysosomal traffic affects the function of astrocytes in ID remains to be clarified. Abnormal astrocytic vesicle traffic underlies another autistic spectrum disorder, the Rett's syndrome, a rare X-linked neurodevelopmental disease. 109 Mutations in the methyl-CpG-binding protein 2 (Mecp2), encoding a multifunctional protein that binds to methylated DNA, acting as a transcriptional regulator, are believed to be responsible. When Mecp2 is re-expressed specifically in astrocytes in the Mecp2-null mice, locomotion and anxiety levels were significantly improved, respiratory abnormalities were restored to a normal pattern and lifespan was greatly prolonged compared with knockout mice. 171 Microtubule-dependent vesicle transport is altered in Mecp2-deficient astrocytes isolated from newborn Mecp2-deficient mice and from human MECP2 p.Arg294* iPSC-derived astrocytes. 109 Administration of microtubule-stabilizing drug (epothilone D) that passes BBB restored microtubule dynamics in Mecp2-deficient astrocytes and in human MECP2 p.Arg294* iPSC-derived astrocytes in vitro. Therefore, not only drugs that target the fusion/fission of vesicles with the plasma membrane as does ketamine, but also molecules that target the integrity of the cytoskeleton are valid targets for new innovative treatments of impaired vesicle networks to be used in future therapies.
Vesicle network dynamics, a target of drugs for treating neurological disturbances
Several drugs, currently used to treat neurological disease, have an effect on astrocytic vesicle dynamics. Vesicle mobility in astrocytes is decreased by fingolimod or FTY720. 121 This drug (Gilenya, Novartis), which is hydrophobic in nature, accumulates in the white matter in the CNS and is used for the treatment of multiple sclerosis. 172 The marketing authorization holder claims that the mechanism of action of this drug in its phosphorylated form is an inhibition of the egress of lymphocytes into the CNS, acting via the sphingosine 1 receptor (SP1R). 173 However, this molecule also acts in the unphosphorylated form directly on astrocytes where it affects astrocytic vesicle dynamics 121 and likely also antigen presentation by astrocytes, which associates with neuroinflammation.
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FTY 720 treatment revealed that traffic of all vesicle types studied were affected 121 ; hence, this drug may modulate the release of other pro-inflammatory factors from astrocytes, including eicosanoids, which are released in the CNS by an ATP-dependent mechanism. 174 Regulated release of ATP from astrocytes 83 participates in the neuroinflammatory CNS states and alterations of traffic of ATP-carrying organelles may additionally affect neuroinflammatory response in diseased conditions. Another established drug, ketamine, an anaesthetic and an antidepressant, affects the vesicle traffic and BDNF release from astroglia. 105 High-resolution membrane capacitance measurements revealed that in the presence of clinically relatively low concentrations, ketamine induces fusion pores to enter into a stable, narrow flickering state. 122 In the presence of ketamine, the fusion pore attains a diameter that is too narrow to permit the discharge of the peptides contained in the vesicle lumen. 105, 175 
